Evidence map›Paper›PMID 33732238›Full record

ArticleFrontiers in immunology2021

Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients.

Ahmed S Fahad, Morgan R Timm, Bharat Madan, Katherine E Burgomaster, Kimberly A Dowd, Erica Normandin, Matías F Gutiérrez-González, Joseph M Pennington, Matheus Oliveira De Souza, Amy R Henry and 11 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Optimized single-cell gates for yeast display screening.Protein engineering, design & selection : PEDS · 2025
    Article
  6. Antibody Data Analysis from Diverse Immune Libraries.Cold Spring Harbor protocols · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 2 countries.

Ahmed S FahadDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS, United States.
Morgan R TimmVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Bharat MadanDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS, United States.
Katherine E BurgomasterViral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Kimberly A DowdViral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Erica NormandinVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Matías F Gutiérrez-GonzálezDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS, United States.
Joseph M PenningtonDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS, United States.
Matheus Oliveira De SouzaDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS, United States.
Amy R HenryVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Farida LabouneVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Lingshu WangVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
David R AmbrozakVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Ingelise J GordonVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Daniel C DouekVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Julie E LedgerwoodVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Barney S GrahamVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Leda R CastilhoFederal University of Rio de Janeiro, COPPE, Cell Culture Engineering Laboratory, Rio de Janeiro, Brazil.
Theodore C PiersonViral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Brandon J DeKoskyDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS, United States.
National Institute of Allergy and Infectious Diseases · USUniversity of Kansas · USUniversidade Federal do Rio de Janeiro · BR

Funding

Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI OROZCO, ROBIN C. · 2016 to 2025
$23.9M
Understanding the mechanobiology of stem cells in a microengineered 3D cardiac tissue environment with cardiomyopathyP20GM103638 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI LUNTE, SUSAN M · 2012 to 2021
$22.1M
The humoral response to Zika virus infection and vaccinationZIAAI001209 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI PIERSON, THEODORE · 2016 to 2025
$22.0M
Host Genomic Factors in Infectious Disease Susceptibility ZIAAI005066 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$17.9M
The Genome Analysis CoreZICAI005133 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2019 to 2025
$16.9M
T Cell Immune Responses To HIV And Other PathogensZIAAI005033 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$11.4M
The HIV ReservoirZIAAI005034 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$7.5M
Innate and Adaptive Immune Responses in SARS-CoV-2 infection (COVID-19)ZIAAI005151 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2020 to 2025
$6.8M
InflammationZIAAI005031 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2024
$5.9M
The influence of evolutionary landscapes on protective antibody developmentR01AI141452 · NIAID · UNIVERSITY OF COLORADO · PI WHITEHEAD, TIMOTHY ANDREW · 2019 to 2023
$2.8M
Comprehensive analysis of human adaptive immune receptors to elucidate correlates of Epstein-Barr virus disease suppressionDP5OD023118 · OD · UNIVERSITY OF KANSAS LAWRENCE · PI DEKOSKY, BRANDON JAMES · 2016 to 2022
$2.2M
Comprehensive molecular and functional analyses of anti-HIV-1 broadly neutralizing antibody repertoiresR21AI143407 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI DEKOSKY, BRANDON JAMES, FORREST, MARCUS LAIRD · 2019 to 2020
$435k
NIAID NIH HHS R01 AI141452NIAID NIH HHS R21 AI143407NIGMS NIH HHS P20 GM103638NIGMS NIH HHS P20 GM113117NIH HHS DP5 OD023118
6 · The paper itself

Abstract

The re-emergence of Zika virus (ZIKV) caused widespread infections that were linked to Guillain-Barré syndrome in adults and congenital malformation in fetuses, and epidemiological data suggest that ZIKV infection can induce protective antibody responses. A more detailed understanding of anti-ZIKV antibody responses may lead to enhanced antibody discovery and improved vaccine designs against ZIKV and related flaviviruses. Here, we applied recently-invented library-scale antibody screening technologies to determine comprehensive functional molecular and genetic profiles of naturally elicited human anti-ZIKV antibodies in three convalescent individuals. We leveraged natively paired antibody yeast display and NGS to predict antibody cross-reactivities and coarse-grain antibody affinities, to perform in-depth immune profiling of IgM, IgG, and IgA antibody repertoires in peripheral blood, and to reveal virus maturation state-dependent antibody interactions. Repertoire-scale comparison of ZIKV VLP-specific and non-specific antibodies in the same individuals also showed that mean antibody somatic hypermutation levels were substantially influenced by donor-intrinsic characteristics. These data provide insights into antiviral antibody responses to ZIKV disease and outline systems-level strategies to track human antibody immune responses to emergent viral infections.

Indexed as

Antibodies, NeutralizingAntibodies, ViralAntibody FormationB-LymphocytesComputational BiologyFlow CytometryHigh-Throughput Nucleotide SequencingHost-Pathogen InteractionsHumansNeutralization TestsPeptide LibraryZika VirusZika Virus InfectionAntibodies, NeutralizingAntibodies, ViralPeptide Libraryantiviral antibodiesB cellsnext-generation sequencingyeast displayZika virus (ZIKV)

Identifiers

PMID33732238
PMCPMC7959826
OpenAlexW3130352657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.